Drug Shortages. A Guide for Assessment and Patient Management
|
|
|
- Merilyn Lindsey
- 10 years ago
- Views:
Transcription
1 Drug Shortages A Guide for Assessment and Patient Management
2 Table of Contents Introduction Managing Drug Shortages Step 1. Checking all medication supply avenues Step 2. Determining how critical a medication is for a patient Step 3. Selecting an alternative medication Step 4. Initiating a new therapy with an alternative medication or discontinuing therapy temporarily Communication between Pharmacists, Prescribers and Patients References Purpose It is well known that drug shortages are not uncommon and, in fact, often occur as a part of the routine day for pharmacists. 1,2,3 This guide presents a systematic approach to assess the impact of drug unavailability and subsequent patient management. It can be applied whenever drug shortages are encountered. This guide is a concise, practical tool for physicians, pharmacists and other prescribers that can be used in any drug shortage situation. The guide was designed to: Present an explicit systematic process to use when faced with a drug shortage. Highlight the unique position of pharmacists, physicians and other prescribers in delivering a strong, reassuring and consistent message to the public regarding the management of drug therapy in the face of drug availability difficulties. Discourage practices of stockpiling or having medications on hand just in-case, and to provide tips for communicating with patients. Introduction Medication therapy is critical in treating and preventing disease and is an integral part of everyday life for many Canadians. The pharmaceutical supply chain of manufacturers, wholesalers, distributors and pharmacists, as well as physicians and governments, acknowledge the importance of having a continuous supply of medications. However, it is possible within today s drug distribution system for glitches to occur, such as short-term back orders or long-term drug unavailability. The challenge for health care providers is to provide seamless, equivalent drug therapy at comparable costs. Assessment requires a critical evaluation of the current situation and potential impact of the shortage on patient outcomes. 4 When an important drug product is not available, practitioners will want to know: reasons for the product s unavailability when the product will be available options for obtaining the drug from alternate sources alternate therapies and their cost consequences related information needs of health care providers and patients. Disruptions in the supply of pharmaceuticals may occur due to several reasons, including: Unexpected increases in utilization of a drug, resulting in a temporary shortage until manufacturing capacity meets demand. Voluntary discontinuation or recalls of a product by a manufacturer. In some situations, other manufacturers market the same drug, but are unaware of the discontinuation, and therefore do not adjust their manufacturing capacity in advance. Withdrawal from the market by Health Canada/manufacturer. Natural disasters (e.g., ice storms and floods). Increased demand due to emergency situations (e.g., mass casualties) or infectious disease outbreaks (e.g., caused by a pandemic influenza). It is important to acknowledge there may be public concern that Canadians will be without essential medicines. As front line health care providers, pharmacists, physicians and other prescribers are in a unique position to deliver a reassuring and consistent message to the public, as well as manage any changes to drug regimens required due to a drug shortage. It also provides an opportunity to do a full medication assessment or review to determine overall appropriateness of drug therapy. CPhA has developed this guide to assist in managing patients in the event of a drug shortage. For drug-specific therapeutic information, pharmacists, physicians and other prescribers are encouraged to refer to drug and therapeutic references (e.g., Therapeutic Choices 5 ; CPS 6 ; etherapeutics 7 ), clinical practice guidelines (e.g., Canadian Medical Association s CPG Infobase at or contact a regional drug information centre. If, in your practice, you are aware of critical drug shortages that necessitate changes to a patient s drug therapy, and have developed a unique way of managing the situation, please share your experience with us. Please call , or us at [email protected]. CPhA will continue to monitor drug supply issues. Pharmacists, physicians and other prescribers must use their professional judgement in using this guide to meet the needs of their own practice settings and situations, and to comply with applicable policies and regulations. This document has been revised from a guide on drug shortages first published by the Canadian Pharmacists Association in 1999, and updated in Drug Shortages Canadian Pharmacists Association 2010
3 Managing Drug Shortages As a general overview of how drug shortages should be resolved, an algorithm (Figure 1) simplifies the management of drug shortages into a number of basic steps and questions. Pharmacists may find that the contents of this section represent steps that they have already internalized and practice on a day to day basis. The shaded boxes represent the three main steps to resolve a medication shortage: 1. Exhausting every avenue to supply the medication 2. Assessing how critical the drug is for the patient 3. Selecting an alternative medication, if required. Step 1. Checking all medication supply avenues Drug shortages are a day to day reality for pharmacists. If a medication is unavailable, the pharmacist investigates different sources for obtaining the medication. Use the following checklist to double check and document the process for obtaining and supplying medications. Figure 2. Checklist for medication supply avenues 1. Is the medication interchangeable with any brand name or generic alternatives? Figure 1. Suggested approach for pharmacists in the management of a drug shortage 2. If the medication is available in other dosage strengths, can the dose be made up using other strengths? Drug shortage encountered Have I exhausted every avenue to supply the drug? 3. If the medication is available in a different formulation, can the drug be supplied in this form? Are there any bioavailability differences which require dosage adjustment? NO Consult checklist for different supply avenues (Figure 2) YES Is this a critical drug? (Figure 3) 4. Can drug supply be obtained through another pharmacy? 5. Can drug supply be obtained through your regular wholesaler or other wholesalers? NO Discuss drug shortage with patient and prescriber* YES Select an appropriate alternative on an individual patient basis (Figures 4 and 5) Discuss drug shortage and alternative drug with patient and prescriber* 6. Can drug supply be obtained directly from the manufacturer? Notes * In many provinces, pharmacists are authorized to adapt a prescription or prescribe an alternative dosage form or medication. Canadian Pharmacists Association 2010 Drug Shortages 3
4 Step 2. Determining how critical a medication is for a patient If a medication is unobtainable and cannot be supplied to a patient, the pharmacist and prescriber must work together to determine how essential or critical the drug is so that the appropriate course of action can be determined. The potential consequences of drug unavailability must be carefully considered for each individual case. A drug shortage also provides an opportunity to do a full medication assessment or review to determine the overall appropriateness of drug therapy. Use the following series of questions to assess the impact of a drug shortage on a patient, and to document the process undertaken with the patient. Table 1 and Figure 3 will assist the health care practitioner in determining how critical a medication is: Level 1 drugs: critical drugs that cannot be missed for even a single dose or day Level 2 drugs: critical drugs that may be missed for greater than one dose or day, but should be reinstituted as soon as possible since they reduce long-term complications of disease and reduce intolerable symptoms of disease Level 3 drugs: non-critical drugs that can safely be withheld for a period of time Table 1: Classification of critical and noncritical drugs and recommended actions Level 1 Level 2 Level 3 Description CRITICAL DRUG Drug should be available for initiation or continuation. CRITICAL DRUG Drug should be available for initiation or continuation. NON-CRITICAL DRUG Drug availability is preferred but not crucial. Drug therapy for disease is essential and cannot be interrupted for even one dose or one day. Drug actions may: be acutely life saving* (e.g., nitroglycerin for angina attack) reduce debilitating symptoms of disease or patient morbidity (e.g., opioids for cancer pain) precipitate dangerous disease events with cessation (e.g., insulin products) *Medications that are not firstline therapies and whose actions are accomplished by alternate therapies are exceptions. Drug therapy for disease is important; however therapy may be interrupted for greater than one dose or one day, but should not be interrupted for extended duration. Drug actions may: be life-saving over time (e.g., diuretics for hypertension) reduce intolerable symptoms of disease or patient morbidity Drug therapy is valuable, yet may be interrupted for an extended duration of time. Drug use may: be based on patient preference only reduce minor symptoms of disease (e.g., H 2 receptor antagonists for dyspepsia) be mostly adjunctive (e.g., montelukast in asthma) add minimal benefit to management of disease be lifestyle drugs (e.g., finasteride for male pattern baldness) Action 1+ Use interchangeable product if medication is unavailable. For single source products, go to Action 2. Use interchangeable product if medication is unavailable. Use interchangeable product if medication is unavailable. Action 2+ Switch to an alternative drug within class, if class effect exists. Consult with prescriber. May consider a switch to an alternative drug within class, if class effect exists. Consult with prescriber. Switching to an alternative drug within class may not be required. Discuss with patient and prescriber. Action 3+ Switch to alternate drug class to ensure continued therapy for disease. Discuss with patient. Consult with prescriber. Substitution with alternate drug class may not be required. Discuss with patient and consult prescriber. Contact patient as soon as medication becomes available. Substitution with alternate drug class is not required. Discuss with patient and prescriber. Inform patient when medication becomes available. +In many provinces, pharmacists are authorized to adapt a prescription or prescribe an alternative dosage form or medication. Note: This classification system should be used as a guide only. Professional judgement is required in determining whether the above classification of a particular drug is appropriate for each patient, based on individual patient need and assessment. 4 Drug Shortages Canadian Pharmacists Association 2010
5 Figure 3. Steps to determine how critical a medication is for a patient 1. What is the seriousness of the disease? For what disease/condition is the drug being used? What are the consequences of untreated disease? h Acutely life-threatening (e.g., angina attack) h Causes debilitating symptoms leading to decreased quality of life (e.g., cancer related pain) h Causes bothersome symptoms with no long-term consequences (e.g., allergic rhinitis) h Serious long-term consequences but not currently bothersome (e.g., hypertension) 3. How essential is the medication in the management of the disease and what are its therapeutic benefits? h Acutely life-saving (e.g., nitroglycerin in unstable angina) h Cures disease (e.g., antibiotics for community acquired pneumonia) h Prevents onset/progression of long-term consequences (e.g., HMG CoA reductase inhibitors for cardiovascular disease) h Reduces/controls bothersome symptoms of disease (e.g., sumatriptan, a 5HT 1 agonist for migraine) 2. What is the effect of abrupt withdrawal of the medication on the patient? On the disease? On other medications being taken by the patient? h Is the medication known to be associated with a withdrawal reaction? (e.g., beta-blockers, SSRIs, anticholinergics) h Will abrupt drug withdrawal precipitate a complication of the disease? (e.g., nitroglycerin for angina) h Had the patient s medications been adjusted to compensate for drug interactions? Will abrupt withdrawal result in the appearance of any drug interactions? (e.g., warfarin drug interactions) 4. Is the patient currently deriving the benefits of the medication? h Is the treatment working? Objective data (e.g., lipid profile) h Is the treatment working? Subjective data. What is the patient s perceived efficacy of the medication? (e.g., PPIs for GERD symptoms) h Is the medication meeting the patient s goals? (e.g., Analgesics may reduce but not completely eliminate pain in patients with cancer pain. Pain reduction may be an acceptable goal for the patient rather than pain elimination.) h Is the patient experiencing any adverse effects from therapy? h Is the patient adherent with drug therapy? h Is the drug therapy still required? Canadian Pharmacists Association 2010 Drug Shortages 5
6 Figure 3. Steps to determine how critical a medication is for a patient continued 5. For how long is the duration of the expected drug shortage? Will the drug be unavailable for: h one day h a few days h several weeks h unknown 6. What patient factors may increase or decrease the impact of the drug shortage on the patient? h Is the patient anxious about the unavailability of his/her medication? h Could this encourage patient non-adherence? h Could this result in the patient perceiving the therapy as not important? 7. For what length of time can the medication be missed without serious detriment to the patient? (See Table 1) t even a single dose or day h Greater than one dose or one day h Extended duration of time (several weeks) 8. Based on the above considerations, how critical is the medication in this situation? (See Table 1) h Level 1 critical drug h Level 2 critical drug h Level 3 non-critical drug The final step in the process is for the physician, pharmacist or other prescriber to integrate all the available information to arrive at a rating of how critical the unavailable medication is to the patient. Classifying medications in this manner makes the prioritization of medications more explicit and helps to determine when a substitute medication must be chosen for the patient, or when a temporary shortage of a medication may be acceptable. Table 1 can be used to grade how critical a certain drug may be and suggests actions based on the level of criticalness. 6 Drug Shortages Canadian Pharmacists Association 2010
7 Step 3. Selecting an alternative medication If a drug is critical for a particular patient, select a substitute that will be effective and tolerable therapy for the patient. Figure 4 describes the factors that should be considered in selecting a substitute medication for a patient. Figure 4. Checklist for selecting an alternative medication 1. Are there acceptable brand name or generic equivalents available? 2. Does the medication belong to a drug category that is known to have a class effect? (e.g., ACE inhibitors, HMG CoA reductase inhibitors) 3. Are there any alternate drug therapies that may be considered? (Refer to current therapeutic references for possible alternatives) 4. How well does each alternate drug therapy work? h Does it provide similar efficacy in managing symptoms? (e.g., PPIs are superior to H 2 receptor antagonists for severe symptoms of GERD.) h Does it have similar efficacy in improving outcomes of disease? (e.g., Digoxin does not reduce overall mortality of heart failure as ACE inhibitors do.) h Has the patient tried any of these alternatives in the past? h How well did they work? 5. When can the alternate drug therapy be expected to begin working? (i.e., The ideal alternate therapy would begin to work as the effects from the original drug wear off.) Canadian Pharmacists Association 2010 Drug Shortages 7
8 Figure 4. Checklist for selecting an alternative medication continued 6. What side effects or toxicities may be expected? h What are the short-term and long-term toxicities? h Do the therapeutic benefits of a medication outweigh its associated toxicities? h If used previously, did the patient experience any side effects or toxicities? 7. Does the patient have any other medical conditions, co morbidities or contraindications to the alternate drug? (e.g., beta-blockers for asthmatics) 9. What other medications is the patient taking? h Do any of these medications interact with potential alternate therapies? h Can dose modifications be made to overcome these drug interactions? 10. Is the alternate drug therapy easily administered? h Can this medication be easily integrated into the patient s routine? h Is the patient capable of undertaking a new regimen? 8. Are there any patient-specific factors that may modify your selection of a substitute drug therapy? h Does the patient have any drug allergies? h Is the patient pregnant or breastfeeding? h Does the age of the patient predispose him/her to certain adverse medication effects? h Is this patient unable to metabolize and/or eliminate this drug? (e.g., ACE inhibitors or digoxin in patients with reduced renal function) 11. Are the alternate drug therapies affordable for the patient? h Is the medication covered by the patient s drug plan? h Due to the shortage, is the alternate medication on special authorization? h Is it more expensive for the patient? 8 Drug Shortages Canadian Pharmacists Association 2010
9 Step 4. Initiating a new therapy with an alternative medication or discontinuing therapy temporarily Figure 5. Checklist for initiating a new therapy or discontinuing therapy 1. What considerations need to be addressed when discontinuing the original medication? h Does the medication need to be tapered downward? If so, by how much and how often should the medication be tapered? (e.g., steroid tapering) h What parameters should be monitored to ensure minimal adverse effects from drug termination? (e.g., beta-blocker withdrawal: monitor heart rate, blood pressure, angina symptoms, etc.) h What parameters should be monitored to ensure that the patient is not experiencing any unnecessary ill effects related to loss of drug action on disease? (e.g., diuretics for heart failure stopped: monitor weight, edema, shortness of breath, etc.) 3. What considerations need to be addressed when the substitute medication is initiated? h Does the substitute medication need to be titrated upward? If so, by how much and how often should the medication be titrated? (e.g., carbamazepine initiation) h What parameters should be monitored to assess onset of drug action and adequacy of drug efficacy? h What parameters should be monitored to detect any adverse effects related to the medication or fast titration of medication? h Is the drug covered by the patient s drug plan? If not, is there a special authorization process to allow for its use? 2. Should the two therapies be overlapped during the switchover? h When should the alternate therapy be initiated to provide continuous drug coverage? h How frequently should the new medication be given to ensure continuous drug coverage? (e.g., fentanyl patch switch to oral morphine tablets) 4. What are the treatment goals? h Include patient in determining if treatment goals have been met. 5. Does the patient require assistance to undertake a new regimen? h What is the patient s comfort level with the new therapy? h What friend or family supports are needed to ensure a smooth transition from original medication to alternative? Canadian Pharmacists Association 2010 Drug Shortages 9
10 Figure 6. Choice of therapy when the original medication becomes available again 1. Should the patient remain on the current medication or switch back to the original? h Refer to Figures 3 and 4 to evaluate the original and alternative medications and identify which medication is preferable for the patient. h How does the patient perceive the effects of the current medication? 2. If the patient is to return to the original medication, what factors should be considered? h Refer to Figure 5 to identify factors that must be considered in switching medications. Communication between Pharmacists, Prescribers and Patients Open lines of communication between pharmacists, physicians or other prescribers and patients are necessary when dealing with drug supply shortages, so that panic is not unnecessarily created when availability of a drug may be temporarily compromised. The public needs to be reassured that stockpiling of medications in case of a shortage outbreak or other event is unwarranted. If there is a temporary shortage of a medication, pharmacists should avoid dispensing large quantities of drugs to individual patients and also stock only the inventory that is needed for their dispensary. Overstocking by some community or hospital pharmacies may result in shortages from the manufacturer or wholesaler for other pharmacies. Physicians and other prescribers can also help in such situations by not prescribing large quantities or for long periods. A team approach between pharmacists, physicians and other prescribers will ensure that a strong and consistent message is delivered to patients. Effective communication and cooperation will become essential when drug shortages do occur. A good working relationship will facilitate a patient-focused, thorough assessment of potential consequences of drug unavailability and development of contingency plans that meet a patient s drug related needs. Reassure patients that they should be able to obtain normal supplies of medication, as they require them. In the event that a pharmacy encounters a particular drug shortage, there are a number of alternative sources of medication supply in the drug distribution system. Encourage patients to reorder medications when 5-7 days of supply remain (e.g., don t let your supply run out). Advise patients not to leave all their medications either at home or work (e.g., carry a few doses with you in case you are delayed. Pharmacists can provide an extra labelled Rx vial for this purpose). When travelling, take a few extra days supply with you and carry them with you on airplanes. Reinforce that stockpiling of medication is not necessary and that obtaining drugs over the Internet is not recommended. The pharmacy supply chain has a demonstrated record of being resilient during many different situations, even emergencies such as natural disasters. Most issues can be quickly and efficiently corrected. Here are some suggested points to share with your patients 3,8,9,10 : 10 Drug Shortages Canadian Pharmacists Association 2010
11 References 1. Woodend AK, Poston J, Weir, K. Drug shortages risk or reality? Can Pharm J 2005; 138(1): Lynas K. Pharmacists in Canada challenged to deal with drug shortages. Can Pharm J 2010; 143(4): American Society of Health-System Pharmacists. Drug Shortages. Available: (accessed September, 2010). 4. ASHP guidelines on managing drug product shortages in hospitals and health systems. Am J Health-Syst Pharm 2009; 66: Gray, J, ed. Therapeutic Choices. 5 th ed. Ottawa (ON): Canadian Pharmacists Association; Compendium of Pharmaceuticals and Specialties, 2010 edition. Ottawa (ON): Canadian Pharmacists Association; etherapeutics [database]. Ottawa (ON): Canadian Pharmacists Association. Available: 8. Canadian Pharmacists Association. Position Statement on Cross-Border Prescription Drug Trade. Ottawa. February Available: (accessed September 7, 2010). 9. Smith DL. Be prepared: keep your medicines close at hand. Taking Control of Your Medicines 2001; 1(2). Available: (accessed September 7, 2010). 10. Travelling with Prescription Medications. Ottawa (ON): Canadian Pharmacists Association; Canadian Pharmacists Association 2010 Drug Shortages 11
12 1785, prom. Alta Vista Drive, Ottawa, ON K1G 3Y6 Telelphone or Fax
Clinical Intervention Definitions
Pharmacy Practice Incentive (PPI) Program Clinical Intervention Definitions $97 million over the life of the Agreement (5 years) Clinical Intervention - Definitions A clinical intervention: is a professional
KENTUCKY ADMINISTRATIVE REGULATIONS TITLE 201. GENERAL GOVERNMENT CABINET CHAPTER 9. BOARD OF MEDICAL LICENSURE
KENTUCKY ADMINISTRATIVE REGULATIONS TITLE 201. GENERAL GOVERNMENT CABINET CHAPTER 9. BOARD OF MEDICAL LICENSURE 201 KAR 9:260. Professional standards for prescribing and dispensing controlled substances.
HAWAII BOARD OF MEDICAL EXAMINERS PAIN MANAGEMENT GUIDELINES
Pursuant to section 453-1.5, Hawaii Revised Statutes, the Board of Medical Examiners ("Board") has established guidelines for physicians with respect to the care and treatment of patients with severe acute
Guidelines on Counseling. Approved by PEIPB
Guidelines on Counseling Approved by PEIPB November 2005 1 Patient Counseling Patient counseling is a key competency element of the Pharmaceutical Care process. Given the advertising for medication in
How To Get A Tirf
Transmucosal Immediate Release Fentanyl (TIRF) Products Risk Evaluation and Mitigation Strategy (REMS) Education Program for Prescribers and Pharmacists Products Covered Under This Program Abstral (fentanyl)
Health Professions Act BYLAWS SCHEDULE F. PART 2 Hospital Pharmacy Standards of Practice. Table of Contents
Health Professions Act BYLAWS SCHEDULE F PART 2 Hospital Pharmacy Standards of Practice Table of Contents 1. Application 2. Definitions 3. Drug Distribution 4. Drug Label 5. Returned Drugs 6. Drug Transfer
MANAGEMENT OF CHRONIC NON MALIGNANT PAIN
MANAGEMENT OF CHRONIC NON MALIGNANT PAIN Introduction The Manitoba Prescribing Practices Program (MPPP) recognizes the important role served by physicians in relieving pain and suffering and acknowledges
Health Professions Act BYLAWS SCHEDULE F. PART 3 Residential Care Facilities and Homes Standards of Practice. Table of Contents
Health Professions Act BYLAWS SCHEDULE F PART 3 Residential Care Facilities and Homes Standards of Practice Table of Contents 1. Application 2. Definitions 3. Supervision of Pharmacy Services in a Facility
PHARMACEUTICAL MANAGEMENT PROCEDURES
PHARMACEUTICAL MANAGEMENT PROCEDURES THE FORMULARY The purpose of Coventry Health Care s formulary is to encourage use of the most cost-effective drugs. The formulary is necessary because the cost of prescription
Pharmacy Program Pre-Test
Last Name: Pharmacy Program Pre-Test * For each question, put a check mark for the one option that you think is correct. 1. A pharmacist receives a security prescription from a known local medical group
Guidelines for the Use of Controlled Substances in the Treatment of Pain Adopted by the New Hampshire Medical Society, July 1998
Guidelines for the Use of Controlled Substances in the Treatment of Pain Adopted by the New Hampshire Medical Society, July 1998 Section I: Preamble The New Hampshire Medical Society believes that principles
Over the Counter Drugs (OTCs): Considerations for Physical Therapy Practice in Canada
Background Over the Counter Drugs (OTCs): Considerations for Physical Therapy Practice in Canada The use of medications or drugs by non-physician health professionals is evolving and is linked to collaboration
CNA and NSO Risk Control Self-assessment Checklist for Nurse Practitioners 1. Self-assessment topic Yes No Actions needed to reduce risks
Risk Control Self-assessment Checklist for Nurse Practitioners This checklist is designed to help nurse practitioners evaluate risk exposures associated with their current practice. For additional nurse
WHEREAS updates are required to the Compensation Plan for Pharmacy Services;
M.O. 23/2014 WHEREAS the Minister of Health is authorized pursuant to section 16 of the Regional Health Authorities Act to provide or arrange for the provision of health services in any area of Alberta
Standards of Practice for Pharmacists and Pharmacy Technicians
Standards of Practice for Pharmacists and Pharmacy Technicians Introduction These standards are made under the authority of Section 133 of the Health Professions Act. They are one component of the law
Abstral Prescriber and Pharmacist Guide
Abstral Prescriber and Pharmacist Guide fentanyl citrate sublingual tablets Introduction The Abstral Prescriber and Pharmacist Guide is designed to support healthcare professionals in the diagnosis of
Maintenance of abstinence in alcohol dependence
Shared Care Guideline for Prescription and monitoring of Acamprosate Calcium Author(s)/Originator(s): (please state author name and department) Dr Daly - Consultant Psychiatrist, Alcohol Services Dr Donnelly
UW School of Dentistry Comprehensive Medication Policy
UNIVERSITY OF WASHINGTON SCHOOL OF DENTISTRY Subject: UW School of Dentistry Comprehensive Medication Policy Policy Number: Effective Date: December 2014 Revision Dates: June 2015 PURPOSE This policy provides
The Federation of State Medical Boards 2013 Model Guidelines for Opioid Addiction Treatment in the Medical Office
The Federation of State Medical Boards 2013 Model Guidelines for Opioid Addiction Treatment in the Medical Office Adopted April 2013 for Consideration by State Medical Boards 2002 FSMB Model Guidelines
Michigan Guidelines for the Use of Controlled Substances for the Treatment of Pain
Michigan Guidelines for the Use of Controlled Substances for the Treatment of Pain Section I: Preamble The Michigan Boards of Medicine and Osteopathic Medicine & Surgery recognize that principles of quality
02 DEPARTMENT OF PROFESSIONAL AND FINANCIAL REGULATION
Effective June 13, 2010 02-313, 02-373, 02-380, 02-383, 02-396 Chapter 21 page 1 02 DEPARTMENT OF PROFESSIONAL AND FINANCIAL REGULATION 313 BOARD OF DENTAL EXAMINERS 373 BOARD OF LICENSURE IN MEDICINE
PRESCRIBING FOR SMOKING CESSATION. (Adapted from the Self-Limiting Conditions Independent Study Program for Manitoba Pharmacists)
PRESCRIBING FOR SMOKING CESSATION (Adapted from the Self-Limiting Conditions Independent Study Program for Manitoba Pharmacists) Acknowledgements The Self-Limiting Conditions Independent Study Program
Medication Utilization. Understanding Potential Medication Problems of the Elderly
Medication Utilization Understanding Potential Medication Problems of the Elderly NICE - National Initiative for the Care of the Elderly WHAT ARE MEDICATION UTILIZATION PROBLEMS AMONG THE ELDERLY? A useful
NUVIGIL (armodafinil) oral tablet
NUVIGIL (armodafinil) oral tablet Coverage for services, procedures, medical devices and drugs are dependent upon benefit eligibility as outlined in the member's specific benefit plan. This Pharmacy Coverage
A pharmacist s guide to Pharmacy Services compensation
Alberta Blue Cross Pharmaceutical Services A pharmacist s guide to Pharmacy Services compensation 83443 (2015/12) GENERAL DESCRIPTION... 3 Details... 3 ASSESSMENT CRITERIA... 3 Assessment for a Prescription
Prior Authorization, Pharmacy and Health Case Management Information. Prior Authorization. Pharmacy Information. Health Case Management
Prior Authorization, Pharmacy and Health Case Management Information The purpose of this information sheet is to provide you with details on how Great-West Life will be assessing and managing your claim
Compensation Plan for Pharmacy Services
Compensation Plan for Pharmacy Services Attachment A Section 1 - Definitions ABC Pharmacy Agreement means an agreement between ABC and a Community Pharmacy as described in Schedule 2.1 of the Alberta Blue
Understanding Alberta s Drug Schedules
Understanding Alberta s Drug Schedules Preface In May 2002, the provincial drug schedules to the Pharmaceutical Profession Act were amended. In April 2007, the Alberta Regulation 66/2007 to the Pharmacy
GUIDELINES ON PREVENTING MEDICATION ERRORS IN PHARMACIES AND LONG-TERM CARE FACILITIES THROUGH REPORTING AND EVALUATION
GUIDELINES GUIDELINES ON PREVENTING MEDICATION ERRORS IN PHARMACIES AND LONG-TERM CARE FACILITIES THROUGH REPORTING AND EVALUATION Preamble The purpose of this document is to provide guidance for the pharmacist
The TIRF REMS Access program is a Food and Drug Administration (FDA) required risk management program
Subject: Important Drug Warning Announcement of a single shared REMS (Risk Evaluation and Mitigation Strategy) program for all Transmucosal Immediate Release Fentanyl (TIRF) products due to the potential
Prior Authorization Guideline
Prior Authorization Guideline Guideline: PDP IBT Inj - Vivitrol Therapeutic Class: Central Nervous System Agents Therapeutic Sub-Class: Opiate Antagonist Client: 2007 PDP IBT Inj Approval Date: 2/20/2007
Administrative Policies and Procedures for MOH hospitals /PHC Centers. TITLE: Organization & Management Of Medication Use APPLIES TO: Hospital-wide
Administrative Policies and Procedures for MOH hospitals /PHC Centers TITLE: Organization & Management Of Medication Use APPLIES TO: Hospital-wide NO. OF PAGES: ORIGINAL DATE: REVISION DATE : السیاسات
CLOSING THE COVERAGE GAP. Pan-Canadian Pharmacare
CLOSING THE COVERAGE GAP Pan-Canadian Pharmacare Prescription drug coverage for all Canadians While the vast majority of Canadians have access to prescription drugs, some Canadians can t afford their medications.
Narcotic drugs used for pain treatment Version 4.3
Narcotic drugs used for pain treatment Version 4.3 Strategy to restrict the pack sizes or the type of packaging available in public pharmacies. 1. Introduction The document describing the strategy of the
Nursing 113. Pharmacology Principles
Nursing 113 Pharmacology Principles 1. The study of how drugs enter the body, reach the site of action, and are removed from the body is called a. pharmacotherapeutics b. pharmacology c. pharmacodynamics
WellDyneRx Mail Service General Questions and Answers
WellDyneRx Mail Service General Questions and Answers I. Location/ Hours of Operation 1. Where is WellDyneRx Mail Pharmacy located? WellDyneRx mail pharmacy has two locations: 1) Centennial, CO, a suburb
Section II When you are finished with this section, you will be able to: Define medication (p 2) Describe how medications work (p 3)
Section II When you are finished with this section, you will be able to: Define medication (p 2) Describe how medications work (p 3) List the different medication effects (p5) List the ways that medications
Adjunctive psychosocial intervention. Conditions requiring dose reduction. Immediate, peak plasma concentration is reached within 1 hour.
Shared Care Guideline for Prescription and monitoring of Naltrexone Hydrochloride in alcohol dependence Author(s)/Originator(s): (please state author name and department) Dr Daly - Consultant Psychiatrist,
North Carolina Medicaid Special Bulletin
North Carolina Medicaid Special Bulletin An Information Service of the Division of Medical Assistance Please visit our Web site at www.ncdhhs.gov/dma July 2007 ATTENTION: All Providers Notice of Change
ExCPT Certified Pharmacy Technician (CPhT) Detailed Test Plan* 100 scored items, 20 pretest items Exam time: 2 hours 10 minutes
ExCPT Certified Pharmacy Technician (CPhT) Detailed Test Plan* 100 scored items, 20 pretest items Exam time: 2 hours 10 minutes # scored items 1. Regulations and Pharmacy Duties 35 A. Overview of technician
Information for Pharmacists
Page 43 by 42 CFR part 2. A general authorization for the release of medical or other information is NOT sufficient for this purpose. Information for Pharmacists SUBOXONE (buprenorphine HCl/naloxone HCl
S1. Which of the following age categories do you fall into? Please select one answer only. 18-44 years of age. 45-64 years of age. 65-74 years of age
Supplemental Materials Supplemental Methods Patient Survey We are presently conducting a market research study to help us better understand some of the challenges experienced by patients taking anticoagulants
How Can We Get the Best Medication History?
How Can We Get the Best Medication History? Stephen Shalansky, Pharm.D., FCSHP Pharmacy Department, St. Paul s Hospital Faculty of Pharmaceutical Sciences, UBC How Are We Doing Now? Completeness of Medication
RMIP Prescription Plan FAQ's
RMIP Prescription Plan FAQ's A new U.S. Pharmacy Benefit Manager has been selected for January 1, 2015 - CVS/caremark. 1) Why is the RMIP changing to CVS/caremark? The Express Scripts contract ends on
Inpatient Anticoagulation Safety. To provide safe and effective anticoagulation therapy through a collaborative approach.
Inpatient Anticoagulation Safety Purpose: Policy: To provide safe and effective anticoagulation therapy through a collaborative approach. Upon the written order of a physician, Heparin, Low Molecular Weight
Managing Your Medications
Managing Your Medications Table of Contents Managing Your Medications Handout 1 Personal health goals & medications... 4 Handout 2 Pharmacists can help you... 6 Handout 3 Managing your medications... 7
An Introduction to the Improved FDA Prescription Drug Labeling
An Introduction to the Improved FDA Prescription Drug Labeling 1 Introduction Mary E. Kremzner, Pharm.D. CDR, U.S. Public Health Service Deputy Director, Division of Drug Information Center for Drug Evaluation
Medicines reconciliation on admission and discharge from hospital policy April 2013. WHSCT medicines reconciliation policy 1
Medicines reconciliation on admission and discharge from hospital policy April 2013 WHSCT medicines reconciliation policy 1 Policy Title Policy Reference Number Medicines reconciliation on admission and
Appendix to Tennessee Department of Health: Tennessee Clinical Practice Guidelines for Outpatient Management of Chronic Non- Malignant Pain
Appendix to Tennessee Department of Health: Tennessee Clinical Practice Guidelines for Outpatient Management of Chronic Non- Malignant Pain Division of Workers Compensation 04.01.2015 Background Opioids
Influenza Vaccine Protocol Agreement (O.C.G.A. Section 43-34-26.1)
Influenza Vaccine Protocol Agreement (O.C.G.A. Section 43-34-26.1) This Influenza Vaccine Protocol Agreement (the "Protocol") authorizes the Georgia licensed pharmacists (the "Pharmacists") or nurses (
MOH CLINICAL PRACTICE GUIDELINES 2/2008 Prescribing of Benzodiazepines
MOH CLINICL PRCTICE GUIELINES 2/2008 Prescribing of Benzodiazepines College of Family Physicians, Singapore cademy of Medicine, Singapore Executive summary of recommendations etails of recommendations
Field Report Field Report Field Report Field Report Field Report
Starting a Pharmaceutical Program Program for Pharmaceutical Care A report written by organizers of volunteerbased health care programs serving the uninsured. 1 to Underserved PHARMACEUTICAL Starting a
SECTION N: MEDICATIONS. N0300: Injections. Item Rationale Health-related Quality of Life. Planning for Care. Steps for Assessment. Coding Instructions
SECTION N: MEDICATIONS Intent: The intent of the items in this section is to record the number of days, during the last 7 days (or since admission/reentry if less than 7 days) that any type of injection,
Pharmacy Handbook. Understanding Your Prescription Benefit
Pharmacy Handbook Understanding Your Prescription Benefit 1 Welcome to Your Prescription Drug Plan! Health Republic Insurance of New York has partnered with US Script to manage your prescription drug benefits.
Princeton University Prescription Drug Plan Summary Plan Description
Princeton University Prescription Drug Plan Summary Plan Description Princeton University Prescription Drug Plan Summary Plan Description January 2015 Contents Introduction... 1 How the Plan Works... 2
Ultram (tramadol), Ultram ER (tramadol extended-release tablets); Conzip (tramadol extended-release capsules), Ultracet (tramadol / acetaminophen)
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.02.35 Subject: Tramadol Acetaminophen Page: 1 of 8 Last Review Date: September 18, 2015 Tramadol Acetaminophen
Depression Support Resources: Telephonic/Care Management Follow-up
Depression Support Resources: Telephonic/Care Management Follow-up Depression Support Resources: Telephonic/Care Management Follow-up Primary Care Toolkit September 2015 Page 29 Role of the Phone Clinician
TRANSMUCOSAL IMMEDIATE RELEASE FENTANYL (TIRF) RISK EVALUATION AND MITIGATION STRATEGY (REMS)
Initial REMS approval: 12/2011 Most recent modification: /2014 TRANSMUCOSAL IMMEDIATE RELEASE FENTANYL (TIRF) RISK EVALUATION AND MITIGATION STRATEGY (REMS) Page 1 of 16 I. GOALS The goals of the TIRF
Community Center Readiness Guide Additional Resource #17 Protocol for Physician Assistants and Advanced Practice Nurses
Community Center Readiness Guide Additional Resource #17 Protocol for Physician Assistants and Advanced Practice Nurses PROTOCOL FOR PHYSICIAN ASSISTANTS AND ADVANCED PRACTICE NURSES 1. POLICY Advanced
CHAPTER 61-03-02 CONSULTING PHARMACIST REGULATIONS FOR LONG-TERM CARE FACILITIES (SKILLED, INTERMEDIATE, AND BASIC CARE)
CHAPTER 61-03-02 CONSULTING PHARMACIST REGULATIONS FOR LONG-TERM CARE FACILITIES (SKILLED, INTERMEDIATE, AND BASIC CARE) Section 61-03-02-01 Definitions 61-03-02-02 Absence of Provider or Consulting Pharmacist
Opioid Treatment Agreement
Opioid Treatment Agreement 1. I understand that my provider and I will work together to find the most appropriate treatment for my chronic pain. I understand the goals of treatment are not to eliminate
SAULT COLLEGE OF APPLIED ARTS AND TECHNOLOGY SAULT STE. MARIE, ONTARIO COURSE OUTLINE
SAULT COLLEGE OF APPLIED ARTS AND TECHNOLOGY SAULT STE. MARIE, ONTARIO COURSE OUTLINE COURSE TITLE: Institutional Pharmacy Dispensing Lab CODE NO. : PTN302 SEMESTER: 3 PROGRAM: AUTHOR: Pharmacy Technician
Outpatient Prescription Drug Benefit
Outpatient Prescription Drug Benefit GENERAL INFORMATION This supplemental Evidence of Coverage and Disclosure Form is provided in addition to your Member Handbook and Health Plan Benefits and Coverage
PharmaCare is BC s public drug insurance program that assists BC residents in paying for eligible prescription drugs and designated medical supplies.
PHARMANET AND PHARMACARE DATA DICTIONARY Date Range: September 1, 1995 to present date, data is provided by calendar year Data Source: BC Ministry of Health Description The PharmaNet system is an online,
Depression is a common biological brain disorder and occurs in 7-12% of all individuals over
Depression is a common biological brain disorder and occurs in 7-12% of all individuals over the age of 65. Specific groups have a much higher rate of depression including the seriously medically ill (20-40%),
Introduction. Background to this event. Raising awareness 09/11/2015
Introduction Primary Care Medicines Governance HSCB Background to this event New class of medicines Availability of training Increasing volume of prescriptions Reports of medication incidents Raising awareness
Prior Authorization Guideline
Prior Authorization Guideline Guideline: CSD - Suboxone Therapeutic Class: Central Nervous System Agents Therapeutic Sub-Class: Analgesics and Antipyretics (Opiate Partial Agonists) Client: County of San
GUIDELINES FOR USE OF PSYCHOTHERAPEUTIC MEDICATIONS IN OLDER ADULTS
GUIDELINES GUIDELINES FOR USE OF PSYCHOTHERAPEUTIC MEDICATIONS IN OLDER ADULTS Preamble The American Society of Consultant Pharmacists has developed these guidelines for use of psychotherapeutic medications
MEDICAL ASSISTANCE BULLETIN
ISSUE DATE September 4, 2015 SUBJECT EFFECTIVE DATE September 9, 2015 MEDICAL ASSISTANCE BULLETIN NUMBER *See below BY Prior Authorization of Opiate Dependence Treatments, Oral Buprenorphine Agents - Pharmacy
Pharmacy and Therapeutics Committee Policies and Procedures
Pharmacy and Therapeutics Committee Policies and Procedures I. Charter... p 2 II. Formulary Principles... p 3 III. Drug Review Process... p 4 7 A. When are Medications Reviewed B. How Are Medications Reviewed
Blueprint for Prescriber Continuing Education Program
CDER Final 10/25/11 Blueprint for Prescriber Continuing Education Program I. Introduction: Why Prescriber Education is Important Health care professionals who prescribe extended-release (ER) and long-acting
Coventry Health Care of Georgia, Inc. Coventry Health and Life Insurance Company
Coventry Health Care of Georgia, Inc. Coventry Health and Life Insurance Company PRESCRIPTION DRUG RIDER This Prescription Drug Rider is an attachment to the Coventry Health Care of Georgia, Inc. ( Health
8 Pharmacy Fees and Subsidies, and Provider Payment
8 Pharmacy Fees and Subsidies, and Provider Payment 8.1 About Fees and Subsidies... 2 8.2 Dispensing Fees... 3 Patient eligibility... 3 Maximum fee... 3 Who can claim a dispensing fee?... 3 Frequent dispensing...
TABLE OF CONTENTS CHAPTER 9 PATIENT COUNSELING AND PROSPECTIVE DRUG USE REVIEW REGULATIONS
TABLE OF CONTENTS CHAPTER 9 PATIENT COUNSELING AND PROSPECTIVE DRUG USE REVIEW REGULATIONS Section 1. Authority 9-1 Section 2. Definitions 9-1 Section 3. Patient Profile Records 9-1 Section 4. Prospective
Your pharmacy, as near as your mailbox Aetna Rx Home Delivery
Quality health plans & benefits Healthier living Financial well-being Intelligent solutions Your pharmacy, as near as your mailbox Aetna Rx Home Delivery www.aetna.com 05.02.308.1-KC B (12/13) Start saving
A G U I D E F O R U S E R S N a l t r e x o n e U
A GUIDE FOR USERS UNaltrexone abstinence not using a particular drug; being drug-free. opioid antagonist a drug which blocks the effects of opioid drugs. dependence the drug has become central to a person
CME Test for AMDA Clinical Practice Guideline. Diabetes Mellitus
CME Test for AMDA Clinical Practice Guideline Diabetes Mellitus Part I: 1. Which one of the following statements about type 2 diabetes is not accurate? a. Diabetics are at increased risk of experiencing
Updates to the Alberta Human Services Drug Benefit Supplement
Updates to the Alberta Human Services Drug Benefit Supplement Effective December 1, 2014 Inquiries should be directed to: Pharmacy Services Alberta Blue Cross 10009 108 Street NW Edmonton AB T5J 3C5 Telephone
HPSJ s Cognitive Services Program 07/2015
HPSJ s Cognitive Services Program 07/2015 Pharmacy & MTM Services Growing demand for MTM services Each year, inappropriate use of medications have led to $1.5 million dollars spent on preventable, medication-related
2015 Travelers Prescription Drug Plan Blue Cross Blue Shield Plan and United Healthcare Choice Plus Plan
2015 Travelers Prescription Drug Plan Blue Cross Blue Shield Plan and United Healthcare Choice Plus Plan Plan Details, Programs, and Policies Table of Contents Click on the links below to be taken to that
CONNECTICUT. Downloaded January 2011 19 13 D8T. CHRONIC AND CONVALESCENT NURSING HOMES AND REST HOMES WITH NURSING SUPERVISION
CONNECTICUT Downloaded January 2011 19 13 D8T. CHRONIC AND CONVALESCENT NURSING HOMES AND REST HOMES WITH NURSING SUPERVISION (d) General Conditions. (6) All medications shall be administered only by licensed
Michigan Board of Nursing Guidelines for the Use of Controlled Substances for the Treatment of Pain
JENNIFER M. GRANHOLM GOVERNOR STATE OF MICHIGAN DEPARTMENT OF COMMUNITY HEALTH LANSING JANET OLSZEWSKI DIRECTOR Michigan Board of Nursing Guidelines for the Use of Controlled Substances for the Treatment
Health Canada Manufacturing and Compounding Drug Products in Canada: A Policy Framework Guidelines for P.E.I. Community and Hospital Pharmacists
Health Canada Manufacturing and Compounding Drug Products in Canada: A Policy Framework Guidelines for P.E.I. Community and Hospital Pharmacists October 2001 In response to pharmacists questions about
Guidelines for Cancer Pain Management in Substance Misusers Dr Jane Neerkin, Dr Chi-Chi Cheung and Dr Caroline Stirling
Guidelines for Cancer Pain Management in Substance Misusers Dr Jane Neerkin, Dr Chi-Chi Cheung and Dr Caroline Stirling Patients with a substance misuse history are at increased risk of receiving inadequate
Rivaroxaban shared care guidelines for the prevention of stroke and embolism in adult patients with nonvalvular atrial fibrillation.
South West Essex Rivaroxaban Shared Care Guideline (SCG) Rivaroxaban shared care guidelines for the prevention of stroke and embolism in adult patients with nonvalvular atrial fibrillation. Introduction
Prior Authorization, Pharmacy and Health Case Management Information. Prior Authorization. Pharmacy Information. Health Case Management
Prior Authorization, Pharmacy and Health Case Management Information The purpose of this information sheet is to provide you with details on how Great-West Life will be assessing and managing your claim
Doncaster & Bassetlaw Medicines Formulary
Doncaster & Bassetlaw Medicines Formulary Section 3.2: Corticosteroids Beclometasone 50, 100 and 250micrograms/dose Clickhaler Clenil Modulite (Beclometasone CFC free) 50, 100, and 250micrograms/dose MDI
Regulation 757-3 STUDENTS November 13, 2013 STUDENTS. Student Health Services and Requirements
STUDENTS November 13, 2013 STUDENTS Student Health Services and Requirements Guidelines for School Staff/Child Care Contractor (CCC) to Carry Out Health Treatment Procedure and/or Emergency Treatment Procedures
Specialty Pharmacy Definition
Isn t All of Special? Developing Services Presented to: 2015 ICHP Annual Meeting Presented on: September 10, 2015 Presented by: Lana Gerzenshtein, Pharm.D., BCPS The speaker has no conflicts of interest
POLICY. 2015 7513 1 of 5. Students ADMINISTRATION OF MEDICATION
1 of 5 ADMINISTRATION OF MEDICATION The school's registered professional nurse may administer medication to a student during the school day under certain conditions. who have been determined by the school
Pharmaceutical Care Lectures. Jay D. Currie, Pharm.D. Fall 2006
Pharmaceutical Care Lectures Jay D. Currie, Pharm.D. Fall 2006 History of the development of the pharmaceutical care model clinical pharmacy practice - 1960's move toward "patient-oriented practice" away
Prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation (AF) with one or more risk factors
News Release For use outside the US and UK only Bayer Pharma AG 13342 Berlin Germany Tel. +49 30 468-1111 www.bayerpharma.com Bayer s Xarelto Approved in the EU for the Prevention of Stroke in Patients
Update on Buprenorphine: Induction and Ongoing Care
Update on Buprenorphine: Induction and Ongoing Care Elizabeth F. Howell, M.D., DFAPA, FASAM Department of Psychiatry, University of Utah School of Medicine North Carolina Addiction Medicine Conference
BOARD NOTICE 271 OF 2013 THE SOUTH AFRICAN PHARMACY COUNCIL RULES RELATING TO GOOD PHARMACY PRACTICE
STAATSKOERANT, 20 DESEMBER 2013 No. 37193 3 BOARD NOTICES BOARD NOTICE 271 OF 2013 THE SOUTH AFRICAN PHARMACY COUNCIL RULES RELATING TO GOOD PHARMACY PRACTICE The South African Pharmacy Council herewith
Provider Manual. Section 18.0 - Case Management and Disease Management
Section 18.0 - Case Management and Disease Management 18.1.1 Introduction 18.2.1 Scope 18.3.1 Objectives 18.4.1 Procedures Case Management 18.4.1-A. Referrals 18.4.1-B. Case Management Mercy Maricopa Acute
Custodial Procedures Manual Table of Contents
Custodial Procedures Manual Table of Contents Page 1. Drug Policies and Procedures 1 A. Procurement of Prescription Drugs 1 i. Prescription drugs may only be accepted from 1 pharmacies and or practitioners.
